Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 5:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 292 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Selective Therapy: Drug Clear all
Terminated Not applicable Interventional Results available

Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN

NCT03206216
View directory record Official record
Conditions
Burning Pain, Impaired Balance, Malignant Ovarian Neoplasm, Numbness, Peripheral Neuropathy, Pain, Acute, Tingling
Interventions
Diode Laser fiber type Selective Stimulator (DLss)
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 1, 2026, 5:43 PM EDT
Terminated Phase 2 Interventional Results available

Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).

NCT05997277
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Deucravacitinib, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 1, 2026, 5:43 PM EDT
Not yet recruiting Not applicable Interventional

DSLT in Normal Tension Glaucoma (NTG) Asian Eyes

NCT07300852
View directory record Official record
Conditions
Normal Tension Glaucoma (NTG), Glaucoma, Open Angle Glaucoma (OAG), Glaucoma, Open Angle
Interventions
Direct Selective Laser Trabeculoplasty (DSLT)
Device
Lead sponsor
Ngoc Nguyen Inc.
Other
Eligibility
20 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 1, 2026, 5:43 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

NCT05438420
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer
Interventions
Q702, Pembrolizumab
Drug · Biological
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 1, 2026, 5:43 PM EDT
Terminated Phase 2 Interventional Results available

Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer

NCT02215161
View directory record Official record
Conditions
Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Selinexor
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.

NCT03672695
View directory record Official record
Conditions
Acute Myeloid Leukaemia
Interventions
S 64315 (also referred as MIK665) and venetoclax
Combination Product
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
New Haven, Connecticut • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Phase 4 Interventional Results available

The ISLAND Study: InSuLa Assessed Needs for Depression

NCT02137369
View directory record Official record
Conditions
Depression
Interventions
Selective serotonin re-uptake inhibitor, Cognitive Behavioral Therapy, Combination treatment (SSRI + CBT)
Drug · Behavioral · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 60 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects

NCT02648672
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
BPN14770, Placebo
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 1, 2026, 5:43 PM EDT
Recruiting Phase 1 Interventional

Pattern Separation in Major Depressive Disorder

NCT07139834
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
SSRI (escitalopram or sertraline), Extended-Release Memantine, Placebo
Drug
Lead sponsor
Jeffrey Miller
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

NCT03316599
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Nab-paclitaxel, Ficlatuzumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Phase 1Phase 2 Interventional

Brief Behavioral Treatment for Anxiety in Young Children

NCT02051192
View directory record Official record
Conditions
Obsessive-compulsive Disorder, Social Phobia, Generalized Anxiety Disorder, Specific Phobia, Separation Anxiety Disorder, Selective Mutism, Anxiety Disorder, Not Otherwise Specified
Interventions
Parent-Led Exposure Therapy, Treatment As Usual
Behavioral · Other
Lead sponsor
University of South Florida
Other
Eligibility
3 Years to 7 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

NCT01173601
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo, SSRI
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
22
States / cities
Irvine, California • La Habra, California • Redlands, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 1, 2026, 5:43 PM EDT
Recruiting No phase listed Observational

Study of CAR-T Therapy in Older Patients

NCT04300998
View directory record Official record
Conditions
Lymphoma, Refractory B-Cell Lymphoma, Lymphoma, B-Cell, DLBCL NOS, High-grade B-cell Lymphoma, Multiple Myeloma
Interventions
Activities of Daily Living/ADLs, Instrumental Activity of Daily Living, Timed Up and Go, Cognition, Geriatric Depression Scale, Social Support, Brief Test of Attention, Trail Making Test, Controlled Oral Word Association Test, Hopkins Verbal Learning Test-Revised, Blood draw
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Not applicable Interventional

Integrated Behavioral Therapy for Treating Children With Selective Mutism

NCT00458198
View directory record Official record
Conditions
Selective Mutism
Interventions
Integrated behavioral therapy (BT)
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
4 Years to 8 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 1, 2026, 5:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AVZO-021 in Patients With Advanced Solid Tumors

NCT05867251
View directory record Official record
Conditions
Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
Interventions
AVZO-021, Palbociclib, Fulvestrant, Letrozole, Ribociclib, Abemaciclib, Carboplatin, Sacituzumab Govitecan-hziy
Drug
Lead sponsor
Avenzo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
11
States / cities
New Haven, Connecticut • Sarasota, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 1, 2026, 5:43 PM EDT
Terminated Not applicable Interventional Results available

Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells

NCT00478036
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Acular LS, Pred Forte, Refresh Tears
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 1, 2026, 5:43 PM EDT
Recruiting Not applicable Interventional

Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

NCT03796559
View directory record Official record
Conditions
Breast Cancer, Axillary Lymph Nodes
Interventions
Magseed Marker
Device
Lead sponsor
Endomagnetics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

NCT02212561
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS), Mixed Phenotype Acute Leukemia (MPAL)
Interventions
Selinexor, Fludarabine, Cytarabine, methotrexate/hydrocortisone/cytarabine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
Phoenix, Arizona • Palo Alto, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 1, 2026, 5:43 PM EDT
Terminated Phase 2 Interventional Results available

PRX-00023 Therapy in Localization-Related Epilepsy

NCT01281956
View directory record Official record
Conditions
Epilepsy, Epilepsy, Temporal Lobe, Partial Epilepsy
Interventions
PRX-00023, Placebo
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 1, 2026, 5:43 PM EDT
Active, not recruiting Phase 1 Interventional

Ultra-fractionated Radiotherapy for Rectal Cancer

NCT04677413
View directory record Official record
Conditions
Rectal Cancer
Interventions
Ultrafractionated radiotherapy for rectal cancer
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Cerebrovascular Control

NCT02936687
View directory record Official record
Conditions
Metabolic Syndrome X
Interventions
NOS Inhibition, ET-1 Inhibition, NOS Inhibition Placebo, 3 Tesla MRI, Intravenous Catheter, Oral Glucose Tolerance Test, ET-1 Inhibition Placebo
Drug · Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Phase 1 Interventional

Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

NCT02485535
View directory record Official record
Conditions
Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Laboratory Biomarker Analysis, Selinexor
Other · Drug
Lead sponsor
University of Chicago
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor

NCT01185340
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo, SSRI
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
20
States / cities
Garden Grove, California • Oakland, California • Temecula, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2018 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Treatments for Depression: Drug Versus Psychotherapy

NCT00043550
View directory record Official record
Conditions
Depression
Interventions
Supportive Expressive Therapy, Sertraline, Pill Placebo, Venlafaxine
Behavioral · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 1, 2026, 5:43 PM EDT